Article in Barron'sHealth, biotech firms target cancer
By CBS.MarketWatch.com
Last Update: 1:11 PM ET May 19, 2001
WASHINGTON (CBS.MW) -- Biotechnology companies and drug makers
developing cancer treatments stand to benefit immensely from new
breakthroughs in science and genomics, according to a Barron's article
Saturday.
Bristol-Myers Squibb (BMY: news, msgs, alerts) , the pharmaceutical
leader in oncology, is spending millions on genomic research to find
new ways to battle the cancer cell.
AstraZeneca (AZN: news, msgs, alerts) , Biomira (BIOM: news, msgs,
alerts) and Onyx Pharmaceuticals (ONXX: news, msgs, alerts) are also
working on anti-cancer vaccines and compounds.
EntreMed (ENMD: news, msgs, alerts) and Genentech (DNA: news, msgs,
alerts ) are among 20 companies with anti-angiogenic drugs under
development. These treatments seek to stop cancer by cutting off the
blood supply to tumors.
Researchers at OSI Pharmaceuticals, ILEX Oncology (ILXO: news, msgs,
alerts) , Pharmacyclics (PCYC: news, msgs, alerts) , MGI Pharma (MOGN:
news, msgs, alerts) , SuperGen (SUPG: news, msgs, alerts) , and
Tularik (TLRK: news, msgs, alerts) are working on advanced
chemotherapy products.
While the incidence rate of heart disease, the country's biggest
killer, is declining, the incidence of cancer is still rising. More
than 1.2 million Americans will be diagnosed with the disease this year.